Datapoint: UCB Snags Fintepla Expansion

Belgian biopharma company UCB scored an expanded label for its drug Fintepla. The FDA this week approved Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare form of epilepsy, in patients 2 and older. The drug will have to face off against Jazz Pharmaceuticals groundbreaking cannabinoid Epidiolex, which was first approved for Lennox-Gastaut in 2018. For the treatment of epilepsy, Fintepla and Epidiolex are covered at parity for 71.8% of all insured lives.

SOURCE: MMIT Analytics, as of 3/28/22

0

0

0 Comments

0

0

• Datapoint